Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment
Suming Wang1, Victor Zota2, Melanie Y Vincent2
1Vigeo Therapeutics, Cambridge, MA, USA. Suming.Wang@vigeotx.com.
NPJ Precision Oncology
|December 3, 2024
Summary
A new cancer therapy, VT1021, boosts thrombospondin-1 (TSP-1) in tumor-infiltrating myeloid-derived suppressor cells (MDSCs). CD36 and CD47 are identified as key biomarkers for patient selection and predicting treatment success.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Most cancer patients lack specific biomarkers for targeted therapies.
- The tumor microenvironment (TME) plays a critical role in cancer progression and treatment resistance.
Purpose of the Study:
- To develop a novel therapeutic agent, VT1021, targeting the TME.
- To identify biomarkers for patient stratification and prognosis in response to VT1021 treatment.
Main Methods:
- VT1021 was developed to induce thrombospondin-1 (TSP-1) expression.
- Myeloid-derived suppressor cells (MDSCs) recruited to the TME were investigated.
- CD36 and CD47 were analyzed as potential biomarkers.
Main Results:
- VT1021 successfully induced TSP-1 expression in MDSCs within the TME.
- CD36 and CD47 were identified as dual biomarkers.
- These biomarkers showed potential for patient stratification and prognosis.
Conclusions:
- VT1021 represents a promising therapeutic strategy by modulating the TME.
- CD36 and CD47 serve as valuable tools for personalizing VT1021 cancer therapy.
